As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Ascendis Pharma As. The largest reported stake is T. Rowe Price Investment Management, Inc.'s, at 10.5%. 14 filings are on record since August 13, 2025 (Schedule 13G/A, May 7, 2026).
Sell to companies like Ascendis Pharma As? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Fmr LLC · Sole voting: 3,425,841 · Shared voting: 0 · Sole dispositive: 3,425,993 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-05
- · Reporting person: Artisan Partners Asset Management Inc. · Sole voting: 0 · Shared voting: 2,422,862 · Sole dispositive: 0 · Shared dispositive: 2,634,024 · SCHEDULE 13G/A, 2026-08-13
- · Holder: Janus Henderson Group Plc · Percent: 6% · SCHEDULE 13G/A
- · Holder: Capital International Investors · Percent: 3.2% · SCHEDULE 13G/A
- · Holder: T. Rowe Price Investment Management, Inc. · Percent: 9.9% · SCHEDULE 13G
Ascendis Pharma As has 14 Schedule 13D or 13G filings on record since 2025-08-13. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 10.5% | 6,506,219 | SCHEDULE 13G/A, 2026-05-07 | 2026-04-30 |
| Westfield Capital Management Company, L.P. | 8.48% | 5,185,696 | SCHEDULE 13G/A, 2026-02-11 | 2025-12-31 |
| Janus Henderson Group Plc | 6% | 3,719,452 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Fmr LLC | 5.2% | 3,425,993 | SCHEDULE 13G/A, 2026-11-05 | 2026-09-30 |
| Artisan Partners Asset Management Inc. | 4.2% | 2,634,024 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
| Capital International Investors | 3.2% | 2,013,285 | SCHEDULE 13G/A, 2026-05-14 | 2026-03-31 |
Holding shares or following this stake? See who's behind Ascendis Pharma As and the warning signs.
Free to see. No signup.
Keep reading
More on Ascendis Pharma As and the records around it.
Ascendis Pharma As elsewhere on the record
Companies that share a holder
- Westfield Capital Management Company, L.P. also filed stake reports on 2 other companies: IMAX CORP (Jun 2026), BICYCLE THERAPEUTICS PLC (Mar 2026)
- Artisan Partners Asset Management Inc. also filed stake reports on 16 other companies: AXALTA COATING SYSTEMS LTD. (Aug 2026), iRhythm Holdings, Inc. (Aug 2026), RADWARE LTD. (Aug 2026)
- Capital International Investors also filed stake reports on 96 other companies: Aurora Innovation, Inc. (Nov 2026), Arxis, Inc. (Aug 2026), Astronics Corp. (Aug 2026)
Watch Ascendis Pharma As
Get an email when Ascendis Pharma As files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Ascendis Pharma As?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Ascendis Pharma As: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ascendis Pharma As covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Fmr LLC | 3,425,841 | 0 | 3,425,993 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| Abigail P. Johnson | 0 | 0 | 3,425,993 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| Artisan Partners Asset Management Inc. | 0 | 2,422,862 | 0 | 2,634,024 | SCHEDULE 13G/A, 2026-08-13 |
| Artisan Partners Holdings LP | 0 | 2,422,862 | 0 | 2,634,024 | SCHEDULE 13G/A, 2026-08-13 |
| Artisan Investments GP LLC | 0 | 2,422,862 | 0 | 2,634,024 | SCHEDULE 13G/A, 2026-08-13 |
| Artisan Partners Limited Partnership | 0 | 2,422,862 | 0 | 2,634,024 | SCHEDULE 13G/A, 2026-08-13 |
The latest filing identifies Ascendis Pharma As by CUSIP K08588103 and gives its principal executive office as TUBORG BOULEVARD 12, HELLERUP (SCHEDULE 13G/A, 2026-11-05).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-13 | Capital International Investors | 5.6% | SCHEDULE 13G |
| 2025-08-14 | Janus Henderson Group Plc | 8% | SCHEDULE 13G/A |
| 2025-08-14 | T. Rowe Price Investment Management, Inc. | 6.4% | SCHEDULE 13G/A |
| 2025-11-14 | Janus Henderson Group Plc | 7.8% | SCHEDULE 13G/A |
| 2025-11-14 | T. Rowe Price Investment Management, Inc. | 4.8% | SCHEDULE 13G/A |
| 2026-02-03 | Artisan Partners Asset Management Inc. | 5.2% | SCHEDULE 13G/A |
| 2026-02-11 | Westfield Capital Management Company, L.P. | 8.48% | SCHEDULE 13G/A |
| 2026-05-06 | Fmr LLC | 6.6% | SCHEDULE 13G/A |
| 2026-05-07 | T. Rowe Price Investment Management, Inc. | 9.9% | SCHEDULE 13G |
| 2026-05-07 | T. Rowe Price Investment Management, Inc. | 10.5% | SCHEDULE 13G/A |
| 2026-05-14 | Capital International Investors | 3.2% | SCHEDULE 13G/A |
| 2026-05-15 | Janus Henderson Group Plc | 6% | SCHEDULE 13G/A |
| 2026-08-13 | Artisan Partners Asset Management Inc. | 4.2% | SCHEDULE 13G/A |
| 2026-11-05 | Fmr LLC | 5.2% | SCHEDULE 13G/A |
Questions about who owns Ascendis Pharma As
Who owns Ascendis Pharma As?
On this page, 4 holders' latest ownership filings report 5% or more of Ascendis Pharma As: T. Rowe Price Investment Management, Inc. (10.5%, Schedule 13G/A, filed 2026-05-07), Westfield Capital Management Company, L.P. (8.48%, Schedule 13G/A, filed 2026-02-11), Janus Henderson Group Plc (6%, Schedule 13G/A, filed 2026-05-15) and Fmr LLC (5.2%, Schedule 13G/A, filed 2026-11-05).
Who are the largest shareholders of Ascendis Pharma As?
By the share each holder's latest filing reports, the largest holders of Ascendis Pharma As on this page are T. Rowe Price Investment Management, Inc. (10.5%), Westfield Capital Management Company, L.P. (8.48%) and Janus Henderson Group Plc (6%).
When did T. Rowe Price Investment Management, Inc. buy into Ascendis Pharma As?
The filings give report dates, not purchase dates. The earliest filing from T. Rowe Price Investment Management, Inc. on this page is the Schedule 13G/A, filed 2025-08-14, reporting 6.4%; its latest, Schedule 13G/A filed 2026-05-07, reports 10.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 14 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Ascendis Pharma As. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.